tetano
Editor, Senior Moderator
Int J Infect Dis
. 2021 Jul 14;S1201-9712(21)00572-5.
doi: 10.1016/j.ijid.2021.07.016. Online ahead of print.
Long-term clinical follow up of patients suffering from moderate to severe COVID-19 infection: A monocentric prospective observational cohort study
Gilles Darcis[SUP] 1 [/SUP], Antoine Bouquegneau[SUP] 2 [/SUP], Nathalie Maes[SUP] 3 [/SUP], Marie Thys[SUP] 3 [/SUP], Monique Henket[SUP] 4 [/SUP], Florence Labye[SUP] 5 [/SUP], Anne-Françoise Rousseau[SUP] 6 [/SUP], Perrine Canivet[SUP] 7 [/SUP], Colin Desir[SUP] 7 [/SUP], Doriane Calmes[SUP] 4 [/SUP], Raphael Schils[SUP] 8 [/SUP], Sophie De Worm[SUP] 8 [/SUP], Philippe Léonard[SUP] 8 [/SUP], Paul Meunier[SUP] 7 [/SUP], Michel Moutschen[SUP] 8 [/SUP], Renaud Louis[SUP] 4 [/SUP], Julien Guiot[SUP] 4 [/SUP]
Affiliations
Abstract
Objectives: Various symptoms and considerable organ dysfunction persist following SARS-CoV-2 infection. Uncertainty remains about the potential mid- and long-term health sequelae. We prospectively studied patients hospitalized for COVID-19 in Liège University Hospital, Belgium, to determine the persistent consequences of Coronavirus disease 2019 (COVID-19).
Methods: We prospectively recruited patients admitted at the University hospital of Liège for moderate to severe confirmed COVID-19, who were discharged between March 2 and October 1, 2020. Follow-up at 3 and 6 months after hospital discharge included demographic and clinical data, biological data, pulmonary function tests (PFT) and chest HRCT scan.
Results: 199 individuals were included in the analysis. Most patients received oxygen supplementation (80.4%). Six months after discharge, 47% and 32% of patients still presented exertional dyspnea and fatigue. PFT at three months revealed a reduced DLCO value (71.6 ± 18.6 %) that significantly increased at six months (p<0.0001). Chest CT showed a high prevalence (in 68.9 % of the cohort) of persisting abnormalities, mostly ground glass opacities. The duration of hospitalization, the admission in ICU or mechanical ventilation were not associated with the persistence of symptoms at 3 months after discharge.
Conclusion: The prevalence of persisting symptoms following hospitalization for COVID-19 is high and stable up to six months after discharge. However, biological, functional and iconographic abnormalities significantly improved overtime.
. 2021 Jul 14;S1201-9712(21)00572-5.
doi: 10.1016/j.ijid.2021.07.016. Online ahead of print.
Long-term clinical follow up of patients suffering from moderate to severe COVID-19 infection: A monocentric prospective observational cohort study
Gilles Darcis[SUP] 1 [/SUP], Antoine Bouquegneau[SUP] 2 [/SUP], Nathalie Maes[SUP] 3 [/SUP], Marie Thys[SUP] 3 [/SUP], Monique Henket[SUP] 4 [/SUP], Florence Labye[SUP] 5 [/SUP], Anne-Françoise Rousseau[SUP] 6 [/SUP], Perrine Canivet[SUP] 7 [/SUP], Colin Desir[SUP] 7 [/SUP], Doriane Calmes[SUP] 4 [/SUP], Raphael Schils[SUP] 8 [/SUP], Sophie De Worm[SUP] 8 [/SUP], Philippe Léonard[SUP] 8 [/SUP], Paul Meunier[SUP] 7 [/SUP], Michel Moutschen[SUP] 8 [/SUP], Renaud Louis[SUP] 4 [/SUP], Julien Guiot[SUP] 4 [/SUP]
Affiliations
- PMID: 34273510
- DOI: 10.1016/j.ijid.2021.07.016
Abstract
Objectives: Various symptoms and considerable organ dysfunction persist following SARS-CoV-2 infection. Uncertainty remains about the potential mid- and long-term health sequelae. We prospectively studied patients hospitalized for COVID-19 in Liège University Hospital, Belgium, to determine the persistent consequences of Coronavirus disease 2019 (COVID-19).
Methods: We prospectively recruited patients admitted at the University hospital of Liège for moderate to severe confirmed COVID-19, who were discharged between March 2 and October 1, 2020. Follow-up at 3 and 6 months after hospital discharge included demographic and clinical data, biological data, pulmonary function tests (PFT) and chest HRCT scan.
Results: 199 individuals were included in the analysis. Most patients received oxygen supplementation (80.4%). Six months after discharge, 47% and 32% of patients still presented exertional dyspnea and fatigue. PFT at three months revealed a reduced DLCO value (71.6 ± 18.6 %) that significantly increased at six months (p<0.0001). Chest CT showed a high prevalence (in 68.9 % of the cohort) of persisting abnormalities, mostly ground glass opacities. The duration of hospitalization, the admission in ICU or mechanical ventilation were not associated with the persistence of symptoms at 3 months after discharge.
Conclusion: The prevalence of persisting symptoms following hospitalization for COVID-19 is high and stable up to six months after discharge. However, biological, functional and iconographic abnormalities significantly improved overtime.